[Our experience in the use of somatostatin in upper digestive hemorrhages].

Minerva Chir

Divisione di Chirurgia Generale, USSL n. 45, Ospedale S. Andrea, Vercelli.

Published: February 1991

The paper illustrates the Authors' personal experience of the use of somatostatin in high digestive hemorrhages. Endoscopy continues to be the principal method for hemorrhage diagnosis and therapy and the additional use of somatostatin undoubtedly accelerates recovery by blocking gastric and pancreatic secretions and blood flow at the splanchnic level.

Download full-text PDF

Source

Publication Analysis

Top Keywords

experience somatostatin
8
[our experience
4
somatostatin upper
4
upper digestive
4
digestive hemorrhages]
4
hemorrhages] paper
4
paper illustrates
4
illustrates authors'
4
authors' personal
4
personal experience
4

Similar Publications

Article Synopsis
  • Managing hypoglycaemia is crucial for insulinoma patients, especially around surgery and in ongoing treatment for inoperable cases.
  • Many patients experience severe and disabling hypoglycaemia due to impaired awareness, increasing the risk of life-threatening episodes.
  • The text outlines an algorithm for hypoglycaemia management based on disease stage and discusses nutritional and pharmacological strategies, including various medications and therapies.
View Article and Find Full Text PDF

Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?

Clin Endocrinol (Oxf)

December 2024

Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds, UK.

With the current therapeutic modalities available to endocrinologists, control of GH and IGF-I is now possible in almost all patients with acromegaly with multi-modality therapy. Despite biochemical control of GH and IGF-I, patients with acromegaly continue to experience impaired quality of life. Although there are likely multiple factors contributing to this dissatisfaction with current medical therapies, in particular the widely utilised injectable long-acting somatostatin receptor ligands (iSRL), is a contributor.

View Article and Find Full Text PDF

Rationale: Pancreaticopleural fistula (PPF) is an infrequent etiology of pleural effusion, characterized by nonspecific thoracic symptoms, which often leads to misdiagnosis and subsequent severe complications. Consequently, early diagnosis is crucial for effective management and the prevention of adverse outcomes. This report presents a rare case of PPF causing bilateral pleural effusions, aiming to enhance clinical recognition of this condition.

View Article and Find Full Text PDF

Patients of head and neck squamous cell carcinoma (HNSCC) experience increased risk of developing second primary cancer (SPC) necessitating active surveillance during their disease course. SPCs are associated with poor prognosis and are the leading cause of long-term morbidity and mortality impacting survival of patients with HNSCC. Small cell neuroendocrine carcinoma (SmNEC) is a rare but aggressive neoplasm with poor prognosis and high risk of local recurrence and distant metastasis.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the effectiveness of somatostatin analogues (SSA) in treating small, non-functioning pancreatic neuroendocrine tumors (PanNETs ≤2 cm) compared to active surveillance.
  • - Data was collected from 72 patients, showing that those treated with SSA had not yet reached median progression-free survival (PFS), whereas the surveillance group had an estimated PFS of 85 months with a 21.9% progression or death rate.
  • - The findings suggest that SSA significantly delays tumor progression and spread in patients with these small PanNETs, highlighting its potential as an effective treatment strategy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!